Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to ...

Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic fibrosis treatment. Progress in that specialty area and two key drug approvals ...

It has been about a month since the last earnings report for FormFactor (FORM). Shares have lost about 16.9% in that time frame, underperforming the S&P 500. Will the recent negative trend ...

News from the Shanghai Stock Exchange points to a change in ownership stake at Factor Bikes, as Zhonglu Holdings “plans to acquire and increase its capital investment in Factor Bikes PTY Ltd.” Brought ...

In trading on Thursday, shares of FormFactor Inc (Symbol: FORM) entered into oversold territory, hitting an RSI reading of 29.6, after changing hands as low as $31.09 per share. By comparison ...

Journavx works differently than other available medications, and its developer, the biotechnology juggernaut Vertex Pharmaceuticals, has positioned it as an important, non-opioid option for pain ...